<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38303065</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19.</ArticleTitle><Pagination><StartPage>46</StartPage><MedlinePgn>46</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">46</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-023-03234-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Post-COVID conditions encompass a range of long-term symptoms after SARS-CoV-2 infection. The potential clinical and economic burden in the United States is unclear. We evaluated diagnoses, medications, healthcare use, and medical costs before and after acute COVID-19 illness in US patients at high risk of severe COVID-19.</AbstractText><AbstractText Label="METHODS">Eligible adults were diagnosed with COVID-19 from April 1 to May 31, 2020, had&#x2009;&#x2265;&#x2009;1 condition placing them at risk of severe COVID-19, and were enrolled in Optum's de-identified Clinformatics<sup>&#xae;</sup> Data Mart Database for&#x2009;&#x2265;&#x2009;12 months before and&#x2009;&#x2265;&#x2009;13 months after COVID-19 diagnosis. Percentages of diagnoses, medications, resource use, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified by age and COVID-19 severity.</AbstractText><AbstractText Label="RESULTS">The cohort included 19,558 patients (aged 18-64 y, n&#x2009;=&#x2009;9381; aged&#x2009;&#x2265;&#x2009;65 y, n&#x2009;=&#x2009;10,177). Compared with baseline, patients during the post-acute phase had increased percentages of blood disorders (16.3%), nervous system disorders (11.1%), and mental and behavioral disorders (7.7%), along with increases in related prescriptions. Overall, there were substantial increases in inpatient and outpatient healthcare utilization, along with a 23.0% increase in medical costs. Changes were greatest among older patients and those admitted to the intensive care unit for acute COVID-19 but were also observed in younger patients and those who did not require COVID-19 hospitalization.</AbstractText><AbstractText Label="CONCLUSIONS">There is a significant clinical and economic burden of post-COVID conditions among US individuals at high risk for severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Amie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Real World Evidence, Pfizer Inc, New York, NY, USA. Amie.scott@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Wajeeha</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Global HEOR, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Farid</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vaccines Medical Development &amp; Scientific Clinical Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambers</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Product Development Statistics, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benigno</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Real World Evidence, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Fusco</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global HEOR, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Global Real World Evidence, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Deepa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Global Real World Evidence, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draica</LastName><ForeName>Florin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccines Medical Development &amp; Scientific Clinical Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwell</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Vaccines Medical Development &amp; Scientific Clinical Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086522" MajorTopicYN="N">Financial Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-COVID conditions</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>All authors are employees of Pfizer Inc and may hold stock or stock options.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38303065</ArticleId><ArticleId IdType="pmc">PMC10836000</ArticleId><ArticleId IdType="doi">10.1186/s12916-023-03234-6</ArticleId><ArticleId IdType="pii">10.1186/s12916-023-03234-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509. doi: 10.1093/ofid/ofaa509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa509</ArticleId><ArticleId IdType="pmc">PMC7665635</ArticleId><ArticleId IdType="pubmed">33403218</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organization. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 8 June 2022.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Post-COVID conditions:&#xa0;information&#xa0;for healthcare providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 23 June 2022.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. New ICD-10-CM code for post-COVID conditions, following the 2019 Novel Coronavirus (COVID-19). Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-Post-COVID-Condition-April-2022-final.pdf. Accessed 8 June 2022.</Citation></Reference><Reference><Citation>McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the post-acute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. 2022;5(5):e2235089. doi: 10.1001/jamanetworkopen.2022.35089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.35089</ArticleId><ArticleId IdType="pmc">PMC9539719</ArticleId><ArticleId IdType="pubmed">36201207</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dowds J, O&#x2019;Brien K, Sheill G, Dyer AH, O&#x2019;Kelly B, et al. Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021;18(6):997&#x2013;1003. doi: 10.1513/AnnalsATS.202009-1175OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202009-1175OC</ArticleId><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen EL, Gossling A, Adam G, Aepfelbacher M, Behrendt CA, Cavus E, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur Heart J. 2022;43(11):1124&#x2013;1137. doi: 10.1093/eurheartj/ehab914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab914</ArticleId><ArticleId IdType="pmc">PMC8755397</ArticleId><ArticleId IdType="pubmed">34999762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713&#x2013;717. doi: 10.15585/mmwr.mm7121e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Steig B, Gaini S, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73(11):e4058&#x2013;e4063. doi: 10.1093/cid/ciaa1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mule G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611.e619&#x2013;611.e616. doi: 10.1016/j.cmi.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo SM, Liu TC, Motwani Y, Sim MS, Viswanathan N, Samras N, et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med. 2022;37(8):1988&#x2013;1995. doi: 10.1007/s11606-022-07523-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07523-3</ArticleId><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11(1):277&#x2013;283. doi: 10.1080/22221751.2021.2023329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2023329</ArticleId><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38&#x2013;42. doi: 10.1016/j.ijid.2021.12.357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.12.357</ArticleId><ArticleId IdType="pmc">PMC8713416</ArticleId><ArticleId IdType="pubmed">34971823</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012&#x2013;8018.</Citation><ArticleIdList><ArticleId IdType="pubmed">34982465</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94(7):2969&#x2013;2976. doi: 10.1002/jmv.27697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27697</ArticleId><ArticleId IdType="pmc">PMC9088621</ArticleId><ArticleId IdType="pubmed">35246846</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M. SARS-CoV-2 variants may induce different long COVID phenotypes. Presented at: European Congress of Clinical Microbiology &amp; Infectious Diseases. Lisbon. 2022.</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS ONE. 2021;16(7):e0254523. doi: 10.1371/journal.pone.0254523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Duarte A, Rivera-Izquierdo M, Guerrero-Fernandez de Alba I, Perez-Contreras M, Fernandez-Martinez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. 2021;19(1):129. doi: 10.1186/s12916-021-02003-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02003-7</ArticleId><ArticleId IdType="pmc">PMC8134820</ArticleId><ArticleId IdType="pubmed">34011359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavery AM, Preston LE, Ko JY, Chevinsky JR, DeSisto CL, Pennington AF, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695&#x2013;1699. doi: 10.15585/mmwr.mm6945e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6945e2</ArticleId><ArticleId IdType="pmc">PMC7660660</ArticleId><ArticleId IdType="pubmed">33180754</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 9 Jan 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009770</ArticleId></ArticleIdList></Reference><Reference><Citation>Yih WK, Hua W, Draper C, Dutcher S, Fuller C, Kempner M, et al. Sentinel COVID-19 natural history master protocol. US Food and Drug Administration. Available at: https://www.sentinelinitiative.org/sites/default/files/Methods/COVID-19-Natural_History_Protocol_v3.0.pdf. Accessed 8 June 2022.</Citation></Reference><Reference><Citation>Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M, Nguyen JL, Scassellati Sforzolini T, et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022;21(4):435&#x2013;451. doi: 10.1080/14760584.2022.2035222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2035222</ArticleId><ArticleId IdType="pmc">PMC8862165</ArticleId><ArticleId IdType="pubmed">35112973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: evidence of mood &amp; cognitive impairment. Brain Behav Immun Health. 2021;17:100347. doi: 10.1016/j.bbih.2021.100347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2021.100347</ArticleId><ArticleId IdType="pmc">PMC8437695</ArticleId><ArticleId IdType="pubmed">34549199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben-Wilke S, Goertz YM, Delbressine JM, Vaes AW, Meys R, Machado FV, et al. The impact of long COVID-19 on mental health: observational 6-month follow-up study. JMIR Ment Health. 2022;9(2):e33704. doi: 10.2196/33704.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/33704</ArticleId><ArticleId IdType="pmc">PMC8914795</ArticleId><ArticleId IdType="pubmed">35200155</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697&#x2013;707. doi: 10.1038/s41586-022-04569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum. 2022;3(5):e221809. doi: 10.1001/jamahealthforum.2022.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannouchos TV, Biskupiak J, Moss MJ, Brixner D, Andreyeva E, Ukert B. Trends in outpatient emergency department visits during the COVID-19 pandemic at a large, urban, academic hospital system. Am J Emerg Med. 2021;40:20&#x2013;26. doi: 10.1016/j.ajem.2020.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.12.009</ArticleId><ArticleId IdType="pmc">PMC7725055</ArticleId><ArticleId IdType="pubmed">33338676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al. Impact of the COVID-19 pandemic on emergency department visits - United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699&#x2013;704. doi: 10.15585/mmwr.mm6923e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6923e1</ArticleId><ArticleId IdType="pmc">PMC7315789</ArticleId><ArticleId IdType="pubmed">32525856</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased influenza activity during the COVID-19 pandemic - United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1305&#x2013;1309. doi: 10.15585/mmwr.mm6937a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6937a6</ArticleId><ArticleId IdType="pmc">PMC7498167</ArticleId><ArticleId IdType="pubmed">32941415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>